Cisatracurium Besylate Injection
Product Images NDC 55150-284

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cisatracurium Besylate (NDC 55150-284). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Maximum Percent Change From Preinjection In Hr And Map During First 5 Minutes After Initial 4 × Ed95 To 8 × Ed95 Cisatracurium Doses In Healthy Adults Who Received Opioid/nitrous Oxide/oxygen Anesthesia (n = 44) (Cisatracurium Fig1)

A scatter plot chart depicting data points in relation to percentage changes on two axes labeled HR (heart rate) on the vertical axis and MAP (mean arterial pressure) on the horizontal axis, each ranging from -60% to +60%. The points cluster near the origin, indicating small variations in HR and MAP.*

FDA Label Image

Figure 2. Percent Change From Preinjection In Hr And Map 10 Minutes After An Initial 4 × Ed95 To 8 × Ed95 Cisatracurium Dose In Patients Undergoing Cabg Surgery Receiving Oxygen/fentanyl/midazolam/anesthesia (n = 54) (Cisatracurium Fig2)

A scatter plot chart showing heart rate (HR) percentage changes versus mean arterial pressure (MAP) percentage changes. The axes range from -60% to +60% for both HR and MAP, with data points clustered near the center.*

FDA Label Image

Package Label-principal Display Panel (20 mg per 10 mL (2 mg per mL))

Label for Cisatracurium Besylate Injection, USP 20 mg per 10 mL (2 mg per mL) in a 10 mL multiple-dose vial. The label warns that the product is a paralyzing agent for intravenous injection containing 0.9% benzyl alcohol as a preservative. It includes storage instructions, distributor information (AuroMedics Pharma LLC), and a barcode.*

FDA Label Image

Package Label-principal Display Panel (20 mg per 10 mL (2 mg per mL))

Packaging label for Cisatracurium Besylate Injection USP 20 mg per 10 mL (2 mg per mL) multiple-dose vials. The label states it is a paralyzing agent for intravenous injection containing 0.9% benzyl alcohol as a preservative. The labeler is Auromedics Pharma LLC, with storage instructions and a warning about respiratory arrest on the side panel. The package contains 10 vials of 10 mL each.*

FDA Label Image

Package Label-principal Display Panel (2 mg/mL)

Label for Cisatracurium Besylate Injection, USP, showing the product name prominently. It includes blank fields for strength in mg/mL, date, time, and by whom it was prepared, along with an instruction to peel off and apply to syringe. The label is orange with black text and a label code P1416958.*

FDA Label Image

Chemical Structure (Cisatracurium Str)

Chemical structure of the active ingredient Cisatracurium Besylate. The diagram shows the molecular arrangement, including two quaternary ammonium groups, aromatic rings with methoxy substitutions, and the besylate counterion, illustrating the compound's detailed chemical configuration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.